House Bill Would Stiffen Penalties for Drug Counterfeiters - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

House Bill Would Stiffen Penalties for Drug Counterfeiters


ePT--the Electronic Newsletter of Pharmaceutical Technology

On Nov. 17, 2011, a bill that would increase penalties for those convicted of trafficking in counterfeit drugs was introduced in the House of Representatives. The Counterfeit Drug Penalty Enhancement Act of 2011, cosponsored by Senators Patrick Leahy (D-VT), Chuck Grassley (R-IA), Michael Bennet (D-CO), and Richard Blumenthal (D-CT) and Representatives Patrick Meehan (R-PA) and Linda Sánchez (D-CA), would set maximum fines of $4 million for an individual and $10 million for a “person other than an individual,” and a maximum jail sentence of life imprisonment for an individual convicted of counterfeit drug trafficking.

Under current law, no distinction is made between counterfeit drugs and other counterfeit consumer items, such as clothing or electronics. The amendment is intended to address the severity of the crime and the potential for harm to the public. “These drugs present a serious threat to the health and safety of people around the world. It’s important we address this threat by imposing harsher penalties on criminals who counterfeit these medicines,” said Senator Grassley in a press release.

Pfizer issued a statement in support of the bill. The company has confirmed counterfeit versions of more than 50 of its medicines in at least 101 countries, according to the statement. Pfizer supports the tougher penalties, saying that they will afford patients greater safety. The proposed legislation “demonstrates that the US is prepared to lead in ensuring safety of the global drugs supply—both by putting a very tough anticounterfeiting law into effect in the world’s largest drugs market and by encouraging partner nations to put similar laws into effect,” according to the statement.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here